| Neurotoxicity of a prion protein fragment G Forloni, N Angeretti, R Chiesa, E Monzani, M Salmona, O Bugiani, ... Nature 362 (6420), 543-546, 1993 | 1171 | 1993 |
| Synthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein C Balducci, M Beeg, M Stravalaci, A Bastone, A Sclip, E Biasini, L Tapella, ... Proceedings of the National Academy of Sciences 107 (5), 2295-2300, 2010 | 621 | 2010 |
| Full length α-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects R Borghi, R Marchese, A Negro, L Marinelli, G Forloni, D Zaccheo, ... Neuroscience letters 287 (1), 65-67, 2000 | 504 | 2000 |
| Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia123 P Quadri, C Fragiacomo, R Pezzati, E Zanda, G Forloni, M Tettamanti, ... The American journal of clinical nutrition 80 (1), 114-122, 2004 | 492 | 2004 |
| Frontotemporal dementia and its subtypes: a genome-wide association study R Ferrari, DG Hernandez, MA Nalls, JD Rohrer, A Ramasamy, JBJ Kwok, ... The Lancet Neurology 13 (7), 686-699, 2014 | 471 | 2014 |
| Sporadic human prion diseases: molecular insights and diagnosis G Puoti, A Bizzi, G Forloni, JG Safar, F Tagliavini, P Gambetti The Lancet Neurology 11 (7), 618-628, 2012 | 446 | 2012 |
| The prevalence of mild cognitive impairment in diverse geographical and ethnocultural regions: The COSMIC Collaboration Perminder, Sachdev S Plos One 10 (11), e0142388, 2015 | 437 | 2015 |
| Apoptosis mediated neurotoxicity induced by chronic application of β amyloid fragment 25–35 G Forloni, R Chiesa, S Smiroldo, L Verga, M Salmona, F Tagliavini, ... Neuroreport 4 (5), 523-526, 1993 | 428 | 1993 |
| Long‐term acetyl‐L‐carnitine treatment in Alzheimer's disease A Spagnoli, U Lucca, G Menasce, L Bandera, G Cizza, G Forloni, ... Neurology 41 (11), 1726-1726, 1991 | 363 | 1991 |
| Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1 G Forloni, F Demicheli, S Giorgi, C Bendotti, N Angeretti Molecular brain research 16 (1-2), 128-134, 1992 | 322 | 1992 |
| The SIRT1 activator resveratrol protects SK‐N‐BE cells from oxidative stress and against toxicity caused by α‐synuclein or amyloid‐β (1‐42) peptide D Albani, L Polito, S Batelli, S De Mauro, C Fracasso, G Martelli, ... Journal of neurochemistry 110 (5), 1445-1456, 2009 | 321 | 2009 |
| Anti-amyloidogenic activity of tetracyclines: studies in vitro G Forloni, L Colombo, L Girola, F Tagliavini, M Salmona FEBS letters 487 (3), 404-407, 2001 | 319 | 2001 |
| JNK signalling: a possible target to prevent neurodegeneration T Borsello, G Forloni Current pharmaceutical design 13 (18), 1875-1886, 2007 | 305 | 2007 |
| TMEM106B regulates progranulin levels and the penetrance of FTLD in GRN mutation carriers N Finch, MM Carrasquillo, M Baker, NJ Rutherford, G Coppola, ... Neurology 76 (5), 467-474, 2011 | 294 | 2011 |
| Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro. F Tagliavini, F Prelli, L Verga, G Giaccone, R Sarma, P Gorevic, B Ghetti, ... Proceedings of the National Academy of Sciences 90 (20), 9678-9682, 1993 | 292 | 1993 |
| Reciprocal control of inflammatory cytokines, IL-1 and IL-6, and β-amyloid production in cultures R Del Bo, N Angeretti, E Lucca, MG De Simoni, G Forloni Neuroscience letters 188 (1), 70-74, 1995 | 288 | 1995 |
| Evaluation of quinacrine treatment for prion diseases A Barret, F Tagliavini, G Forloni, C Bate, M Salmona, L Colombo, ... Journal of virology 77 (15), 8462-8469, 2003 | 269 | 2003 |
| Tetracyclines affect prion infectivity G Forloni, S Iussich, T Awan, L Colombo, N Angeretti, L Girola, I Bertani, ... Proceedings of the National Academy of Sciences 99 (16), 10849-10854, 2002 | 253 | 2002 |
| Neuroprotective properties of resveratrol in different neurodegenerative disorders D Albani, L Polito, A Signorini, G Forloni Biofactors 36 (5), 370-376, 2010 | 244 | 2010 |
| Alzheimer’s disease, oligomers, and inflammation G Forloni, C Balducci Journal of Alzheimer’s Disease 62 (3), 1261-1276, 2018 | 237 | 2018 |
Roberto ChiesaLaboratory of Prion Neurobiology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, MilanVerified email at marionegri.it
